Universe Pharmaceuticals INC Announces Strategic Alliance with Jiangxi Province Institute of Materia Medica to Conduct Research in Traditional Chinese Medicine

Ji’an, Jiangxi, China, January 04, 2022 (GLOBE NEWSWIRE) – Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company has entered into two strategic cooperation agreements (the “Agreements”) with the Jiangxi Province Institute of Materia Medica (“Jiangxi IMM”), an inspection and testing institution fully funded by the Jiangxi Province Medical Products Administration, which promotes the development of the pharmaceutical industry by conducting research on Chinese and Western medical devices and drugs.

In accordance with the agreements, the Company authorized Jiangxi IMM to conduct six studies on the quality standard of traditional Chinese medicine formula granules, including Isatis Root Granule, Epimedium, Sophora Flavescens, Ginseng, Angelica and Astragalus. The Company will provide materials and related samples to Jiangxi IMM for these studies. Studies should be conducted in accordance with the requirements and standards of the Pharmacopoeia of the People’s Republic of China, including stability, reproducibility and sample size. Upon completion of each of the six studies, Jiangxi IMM will receive a payment from the Society.

As part of the agreements, the two sides agreed to collaborate on scientific research, talent development and project collaboration to create more formulas for traditional Chinese medicine. Leveraging their expertise, the two sides expect to further research and expand on the theory of the compatibility of traditional Chinese medicine, the material basis of the medicinal effect and the improvement of the pharmacological effect and quality standards, and get involved in the design and evaluation of the traditional Chinese intelligent manufacturing process. medicine pills.

Mr. Gang Lai, President and CEO of Universe Pharmaceuticals INC, said, “We are delighted to partner with Jiangxi IMM. Adding Jiangxi IMM’s vast experience to our own research and development (“R&D”) capability will provide us with a strategic advantage and may bring new business opportunities. By engaging a medical R&D partner, we hope to accurately identify, quantify and improve the function of current pharmaceuticals in order to provide better medical solutions to our customers. We believe that Jiangxi IMM’s studies will help further improve the quality of our products and we are positioned to continue to grow and develop our traditional Chinese medicine products.

On Jiangxi Province Institute MateriaMedication

Affiliated with the Administration of Medical Products of Jiangxi Province, the Institute of Medical Materials of Jiangxi Province was established in 1973. The Institute of Medical Materials of Jiangxi Province has undertaken a large number of research projects. national and provincial scientific research and has successfully developed dozens of new national level projects. Chinese and Western Medicines and Functional Food Supplements. For more information, visit the institute’s website at http://www.jxmdt.org.cn/.

About Universe Pharmaceuticals INC

Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a manufacturer and distributor of pharmaceuticals in China. The Company specializes in the manufacture, marketing, sale and distribution of products derived from traditional Chinese medicine targeting the elderly with the aim of remedying their physical conditions related to the aging process and promoting their general well-being. . The Company also distributes and sells biomedical drugs, medical instruments, pieces of traditional Chinese medicine, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold to 30 provinces in China. For more information, visit the company’s website at http://www.universe-pharmacy.com/.

Forward-looking statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections regarding future events and financial trends. which, in the Company’s opinion, could affect its financial condition, results of operations, business strategy and financial needs. Investors may identify these forward-looking statements by words or phrases such as “may”, “will”, “expect”, “anticipate”, “aim”, “estimate”, “intend”, ” plan ”,“ believe ”,“ potential ”,“ continue ”,“ is / are likely to ”or other similar expressions. The Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as required by law. While the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee that such expectations will prove to be correct, and the Company cautions investors that actual results may differ materially from anticipated results and encourages investors to review d ” other factors that may affect its future results in the company’s registration statement and in its other documents filed with the SEC.

For more information please contact:

Ascent Investor Relations LLC
Tina Xiao
President
Telephone: 917-609-0333
Email: [email protected]